# An Open Label Study for Participants With Rheumatoid Arthritis

> **NCT01215942** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 1086 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** LY2127399

## Key facts

- **NCT ID:** NCT01215942
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 1086 (ACTUAL)
- **Why stopped:** Insufficient efficacy observed in study BCDM (NCT01198002) and BCDV (NCT01202773).
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215942, "An Open Label Study for Participants With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01215942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*